Associated Papers
Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities.
Trejo-Lopez JA et al.
Brain Pathology (zurich, Switzerland), 2026
H3-3A gene mutation analysis in giant cell tumor of bone and its histologic mimics: A single institutional study from India.
Uppin SG et al.
Annals of Diagnostic Pathology, 2026
Resource: A compendium of HLA types and expression in pediatric cancer models.
Guan Y et al.
Iscience, 2025
Diffuse hemispheric glioma, H3 G34-mutant, a single centre experience and histopathological analysis.
Amer F et al.
Virchows Archiv : an International Journal of Pathology, 2025
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
Miller AR et al.
Bmc Cancer, 2025
Diffuse Hemispheric Glioma, H3 G34-Mutant With Prominent Perivascular Invasion in a Middle-Aged Man: A Case Report and Literature Review of Middle-Aged and Elderly Cases.
Yuzawa S et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2025
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
Le Rhun E et al.
Neuro-oncology, 2025
Systematic comprehension of genomics and mutational landscape of glioma: A goal towards advanced therapeutics.
Dakal TC et al.
Neuroscience, 2025
MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.
Friker LL et al.
Acta Neuropathologica, 2025
A patient with heterochronous double primary tumor of basal ganglia germ cell tumors followed by diffuse hemispheric glioma: a case report.
He Z et al.
Child's Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery, 2024
H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications.
Angelico G et al.
Cancers, 2024
Genomic Insights Into High-Grade Infarct-Associated Bone Sarcomas.
Tvrdik T et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.
Ikeuchi H et al.
Oncogene, 2024
Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals.
Layo-Carris DE et al.
European Journal of Human Genetics : Ejhg, 2024
Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
Donev K et al.
Journal of Neuropathology and Experimental Neurology, 2024
A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors.
Haberberger JF et al.
The Oncologist, 2024
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Wood MD et al.
Acta Neuropathologica Communications, 2023
A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA et al.
Acta Neuropathologica, 2023
Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
Stundon JL et al.
Neuro-oncology, 2023
H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.
Lavrador JP et al.
Acta Neurochirurgica, 2023
Concordance analysis of cerebrospinal fluid with the tumor tissue for integrated diagnosis in gliomas based on next-generation sequencing.
Wang Q et al.
Pathology Oncology Research : Por, 2023
Druggable genomic landscapes of high-grade gliomas.
Ghanem P et al.
Frontiers in Medicine, 2023
Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers.
Lim WC et al.
Frontiers in Immunology, 2023
Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.
Zakharova G et al.
International Journal of Molecular Sciences, 2022
Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas.
Wolter M et al.
Acta Neuropathologica Communications, 2022
Diagnostic Utility of Genetic and Immunohistochemical H3-3A Mutation Analysis in Giant Cell Tumour of Bone.
Wągrodzki M et al.
International Journal of Molecular Sciences, 2022
A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study.
Xie X et al.
Frontiers in Oncology, 2022
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.
Tsai JM et al.
The Oncologist, 2021
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.
He C et al.
Nature Communications, 2021
American Association of Neuropathologists, Inc. Abstracts of the 97th Annual Meeting June 10-13, 2021 St. Louis, Missouri.
Unknown Author
Journal of Neuropathology and Experimental Neurology, 2021
A common classification framework for histone sequence alterations in tumours: an expert consensus proposal.
Leske H et al.
The Journal of Pathology, 2021
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
Patel RR et al.
Pediatric Blood & Cancer, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M et al.
Frontiers in Immunology, 2020
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Froyen G et al.
Cancers, 2019
A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL et al.
European Journal of Cancer (oxford, England : 1990), 2019
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
Guerreiro Stucklin AS et al.
Nature Communications, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Miller AM et al.
Nature, 2019
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW et al.
Plos One, 2019
Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR).
Gamberi G et al.
Pathology, Research and Practice, 2018
Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours.
Izquierdo E et al.
Oncotarget, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A et al.
The Oncologist, 2017
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors.
Ramkissoon SH et al.
Neuro-oncology, 2017